1. Home
  2. BCG vs TVRD Comparison

BCG vs TVRD Comparison

Compare BCG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.69

Market Cap

32.6M

Sector

N/A

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$3.97

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
TVRD
Founded
2016
2017
Country
United States
United States
Employees
150
12
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6M
34.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BCG
TVRD
Price
$1.69
$3.97
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
80.2K
34.4K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$2.75
52 Week High
$3.44
$43.65

Technical Indicators

Market Signals
Indicator
BCG
TVRD
Relative Strength Index (RSI) 35.88 55.73
Support Level $1.46 $3.81
Resistance Level $1.90 $4.32
Average True Range (ATR) 0.19 0.28
MACD -0.04 0.03
Stochastic Oscillator 5.62 60.60

Price Performance

Historical Comparison
BCG
TVRD

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: